• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

MAC regulations: their predicted economic impact on pharmaceutical reimbursement.

作者信息

Gammill C G, Francis W R

出版信息

Contemp Pharm Pract. 1981 Winter;4(1):32-6.

PMID:10298086
Abstract

The Maximum Allowable Cost (MAC) regulations, Part 19 of Subtitle A of Title 45 of the Code of Federal Regulations, were promulgated as a method of cost containment applicable to a component of the escalating health care expenditures. This study predicted the economic impact of the MAC regulations on the Medicaid program of Georgia. Reimbursements for Medicaid prescription drug products by the Georgia Department of Medical Assistance for 1976-1977 were compared with the reimbursements for drug products that would have been paid under the MAC regulation limitations had the MAC regulations been in force during the time period studied. The cost per unit of a purposive sample of 386 drug entities sorted into eight code groups was compared with the MAC-regulated cost per unit reimbursements. Significant differences in cost were noted for three of the eight code groups. For these groups, reimbursements of before MAC-regulated drug product cost per unit were greater than reimbursements for predicted MAC-regulated drug product cost per unit. Further analysis of the data predicted a reduction of reimbursements for the eight classes of prescription drug products studied to be 24.42%. This reduction compares favorably with the projected savings of 22-36% reported by the Task Force on Prescription Drugs.

摘要

相似文献

1
MAC regulations: their predicted economic impact on pharmaceutical reimbursement.
Contemp Pharm Pract. 1981 Winter;4(1):32-6.
2
Pharmaceutical reimbursement and drug cost control: the MAC experience in Maryland.
Inquiry. 1983 Spring;20(1):76-87.
3
Differences in the cost of antidepressants across state Medicaid programs.各州医疗补助计划中抗抑郁药物成本的差异。
J Ment Health Policy Econ. 2008 Mar;11(1):33-47.
4
Pharmaceutical Reimbursement Board; final maximum allowable cost (MAC) determinations for certain drug products--Health Care Financing Administration. Final notice.药品报销委员会;某些药品的最终最高允许成本(MAC)确定——医疗保健财务管理局。最终通知。
Fed Regist. 1982 Dec 30;47(251):58370-2.
5
Evaluation of the maximum allowable cost program.最高允许成本计划评估
Health Care Financ Rev. 1983 Mar;4(3):71-82.
6
A comparative study of current Medicaid prescription reimbursement (MAC/EAC) (maximum allowable cost/estimated acquisition cost) with prescription reimbursement based on a competitive market.
J Pharm Mark Manage. 1988;3(2):37-46. doi: 10.3109/j058v03n02_04.
7
Medicaid program; prescription drugs. Final rule with comment period.医疗补助计划;处方药。有意见征求期的最终规定。
Fed Regist. 2007 Jul 17;72(136):39141-245.
8
Medicare program; Medicare prescription drug discount card. Interim final rule with comment period.医疗保险计划;医疗保险处方药折扣卡。有意见征求期的暂行最终规则。
Fed Regist. 2003 Dec 15;68(240):69839-927.
9
State Medicaid prescription drug expenditures for Medicare-Medicaid dual eligibles: estimates of Medicaid savings and federal expenditures resulting from expanded Medicare prescription coverage.针对医疗保险 - 医疗补助双重资格者的州医疗补助处方药支出:扩大医疗保险处方药覆盖范围带来的医疗补助节省及联邦支出估算。
Issue Brief (Commonw Fund). 2003 Apr(627):1-12.
10
Pharmaceutical Reimbursement Board; suspension of maximum allowable cost limits on specific drug products--HCFA.药品报销委员会;暂停特定药品的最高允许成本限制——医疗保健财务管理局
Fed Regist. 1983 Sep 30;48(191):44931.